Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid

Alzheimer s & Dementia(2024)10.1002/alz.13764Source: DataRank Database

Clinical validation of the PrecivityAD2 blood test: A mass spectrometry‐based test with algorithm combining %p‐tau217 and Aβ42/40 ratio to identify presence of brain amyloid is a research paper published in Alzheimer s & Dementia (2024). On theSindex it has a DataRank of 0. It has been cited 112 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access112 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)OA: hybridTopics (79)IDs (PubMed)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (25)

Kristopher M. Kirmess ORCID,Stephanie Eastwood,Traci L. Wente‐Roth,Faith Irvin,Mary S. Holubasch

Live enrichment

PubMed:38491912

National Institutes of Health

Grant: R44 AG059489

BrightFocus Foundation

Grant: CA2016636

Alzheimer's Drug Discovery Foundation

Grant: GC‐201711‐2013978

National Institutes of Health

Grant: 4R44AG059489-02

Plasma Abeta isoform concentrations in cognitively impaired patients at risk for amyloidosis

NIA NIH HHS

Grant: P30 AG072972

Alzheimer's Drug Discovery Foundation

Grant: GC-201711-2013978

Gerald and Henrietta Rauenhorst Foundation

hybridLicense: cc-by-nc-nd

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/alz.13764

publisherhttps://alz-journals.onlinelibrary.wiley.com/doi/pdf/10.1002/alz.13764

repositoryhttps://escholarship.org/content/qt5hw1q94s/qt5hw1q94s.pdf

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11095426/pdf/ALZ-20-3179.pdf

https://doi.org/10.1002/alz.13764

Fields of Study

03 medical and health sciences0303 health sciencesHumansAmyloid beta-PeptidesFemaleMaletau ProteinsAlzheimer DiseaseAgedAlgorithmsPositron-Emission TomographyPeptide FragmentsBrainBiomarkersMass SpectrometryMiddle AgedAged, 80 and overROC Curve

MeSH Terms

HumansAmyloid beta-PeptidesFemaleMaletau ProteinsAlzheimer DiseaseAgedAlgorithmsPositron-Emission TomographyPeptide FragmentsBrainBiomarkersMass SpectrometryMiddle AgedAged, 80 and overROC Curve

Keywords

MaleAgingClinical Sciences610diagnostictau ProteinsNeurodegenerativeAlzheimer's DiseaseMass SpectrometryAlzheimersClinical ResearchAlzheimer Diseaseclinical validityAcquired Cognitive Impairment80 and overHumansp-tau217Research ArticlesAgedAged, 80 and overAmyloid beta-PeptidesBiomedical and Clinical Sciencesp‐tau217NeurosciencesAlzheimer's Disease including Alzheimer's Disease Related Dementias (AD/ADRD)BrainMiddle AgedAlzheimer'sPeptide FragmentsBrain Disorders4.1 Discovery and preclinical testing of markers and technologiesamyloid betaROC CurveGeriatricsPositron-Emission TomographyNeurologicalBiomedical ImagingWomen's HealthBiological psychologyDementiaFemaleblood biomarkerAlgorithmsBiomarkers4.2 Evaluation of markers and technologies

Sustainable Development Goals

SDG 3: 3. Good health